AVROBIO, Inc. to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc. (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that members of its senior management team are scheduled to participate in five upcoming investor conferences.

Citi’s 14th Annual Biotech Conference

Date: Wednesday, September 4, 2019

Location: The Four Seasons, Boston, MA

Wells Fargo Securities 2019 Healthcare Conference

Date: Thursday, September 5, 2019

Location: The Westin Copley Place Hotel, Boston, MA

Janney Healthcare Conference 2019

Date: Monday, September 9, 2019

Location: The Union League Club, New York, NY

H.C. Wainwright 21st Annual Global Investment Conference

Date: Monday, September 9, 2019

Location: Lotte New York Palace Hotel, New York, NY

Morgan Stanley 17th Annual Global Healthcare Conference

Date: Tuesday, September 10, 2019

Location: Grand Hyatt, New York, NY

A live webcast of the presentation at the Wells Fargo Securities 2019 Healthcare Conference on September 5, 2019 (at 8:00 a.m. ET) and the presentation at the H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019 (at 5:05 p.m. ET) will be available on the investors section of the AVROBIO company website at www.avrobio.com. After the live webcasts, the events will remain archived on the AVROBIO website for 90 days.

About AVROBIO, Inc.

AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.


Investor Contact:

Christopher F. Brinzey

Westwicke, an ICR Company



Media Contact:

Tom Donovan

Ten Bridge Communications



error: Content is protected !!